Vaxil Historical Income Statement
| VXL Stock | CAD 0.01 0.00 0.00% |
Historical analysis of Vaxil Bio income statement accounts such as Selling General Administrative of 114, Selling And Marketing Expenses of 17.1, Other Operating Expenses of 241 or Cost Of Revenue of 1.7 K can show how well Vaxil Bio performed in making a profits. Evaluating Vaxil Bio income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Vaxil Bio's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Vaxil Bio latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Vaxil Bio is a good buy for the upcoming year.
Vaxil |
About Vaxil Income Statement Analysis
Vaxil Bio Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Vaxil Bio shareholders. The income statement also shows Vaxil investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Vaxil Bio Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Vaxil Bio. It is also known as Vaxil Bio overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Cost Of Revenue
Cost of Revenue is found on Vaxil Bio income statement and represents the costs associated with goods and services Vaxil Bio provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Total Revenue
Total revenue comprises all receipts Vaxil Bio generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Most accounts from Vaxil Bio's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Vaxil Bio current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxil Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Vaxil Bio's Total Other Income Expense Net is fairly stable compared to the past year. Income Tax Expense is likely to climb to about 13.3 K in 2024, whereas Selling And Marketing Expenses is likely to drop 17.10 in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 986K | 584K | 254.0 | 241.3 | Cost Of Revenue | 25K | 2K | 1.8K | 1.7K |
Vaxil Bio income statement Correlations
Click cells to compare fundamentals
Vaxil Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Vaxil Bio income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Selling General Administrative | 383K | 724K | 428K | 239K | 120.0 | 114.0 | |
| Gross Profit | (100K) | (57K) | (25K) | (2K) | (2.3K) | (2.4K) | |
| Other Operating Expenses | 1.1M | 1.3M | 986K | 584K | 254.0 | 241.3 | |
| Operating Income | (1.1M) | (1.3M) | (986K) | (584K) | (254.0) | (266.7) | |
| Ebitda | (1.0M) | (1.3M) | (961K) | (582K) | (252.0) | (264.6) | |
| Cost Of Revenue | 100K | 57K | 25K | 2K | 1.8K | 1.7K | |
| Total Operating Expenses | 1.1M | 1.3M | 986K | 584K | 254.0 | 241.3 | |
| Income Before Tax | (1.2M) | (1.4M) | (986K) | (584K) | (254.0) | (266.7) | |
| Net Income | (1.2M) | (1.4M) | (986K) | (584K) | (254.0) | (266.7) | |
| Depreciation And Amortization | 100K | 57K | 25K | 2K | 167.9K | 176.3K | |
| Ebit | (1.1M) | (1.3M) | (986K) | (584K) | (168.1K) | (176.6K) | |
| Net Income From Continuing Ops | (1.2M) | (1.4M) | (986K) | (584K) | (254K) | (266.7K) | |
| Research Development | 750K | 619K | 539K | 343K | 114.0 | 108.3 | |
| Net Income Applicable To Common Shares | (1.0M) | (1.2M) | (1.4M) | (986K) | (1.1M) | (1.2M) | |
| Net Interest Income | 5K | (6K) | (11K) | 4K | 3.6K | 3.8K | |
| Reconciled Depreciation | 56K | 100K | 57K | 25K | 2K | 0.0 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vaxil Stock Analysis
When running Vaxil Bio's price analysis, check to measure Vaxil Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxil Bio is operating at the current time. Most of Vaxil Bio's value examination focuses on studying past and present price action to predict the probability of Vaxil Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxil Bio's price. Additionally, you may evaluate how the addition of Vaxil Bio to your portfolios can decrease your overall portfolio volatility.